REBAVAC - Novel opportunities to develop vaccines to control anti-bacterial resistant encapsulated bacteria: from the trials back to the laboratory. The Reverse Clinical Vaccinology approach (Life sciences, genomics and biotechnology for health) (2006-09-01 - 2007-08-31) (»add to infobox)

Vaccination appears to be the best way to defeat antibiotic resistant bacteria. Conjugated polysaccharide vaccines are quite efficacious and represent a good solution to elicit protective immune responses to encapsulated bacteria. However, the analysis of the effects of using for several years conjugated polysaccharide vaccines to encapsulated bacteria is raising some curiosity leading to a re-thinking about how immunity to polysaccharide is elicited following vaccination. With this project we aim to organise a Workshop involving the most important vaccine experts worldwide to address several questions raised from the analysis of the vaccination trial results in order to develop new ideas to improve vaccination to antibiotic resistant bacteria. The main objectives of the Workshop are: i) to evaluate the current status of conjugated vaccines against encapsulated bacteria; ii) to verify the parameters used to define immune memory after vaccination; iii) to indicate ways to improve protection against antibiotic resistant bacteria. In addition, the role of carrier proteins and the current status of protein-based vaccines will be analysed. In a training session young scientists will be given the opportunity to present their research, whereas a round table with industries representatives, policy makers and scientists will be organised to discuss the efficacy of vaccination and the economical and political aspects related with the development, use and distribution of vaccines to encapsulated bacteria. A final Consensus Document on "Future trends in vaccine development to defeat antibiotic resistant bacteria" will be prepared and made available to the public.

COORDINATOR (1/1)

RELATED THEMATIC AREAS (1/1)